These studies highlight the importance of CD11c+T-bet+ B cells in the pathogenesis of SLE, and suggest that targeted depletion of these cells will reduce disease severity in autoimmune diseases wherein these cells have been implicated; however, no such pharmacological treatments currently exist. This evidence concerns the gene ITGAX and systemic lupus erythematosus.